CLOSED-ACCESS TECHNOLOGY PARTNERSHIP · ADMISSION BY QUALIFICATION ONLY

Science Monopoly.
Partner Mandate.

One technology. One exclusive partner. Zero dilution. Every track is NDA-protected from first contact, ISO 27001-enforced throughout, and terminates in full IP transfer — or the technology is permanently removed from partner consideration.

REQUEST Q4 ALLOCATION Browse Research Library
OPERATIONAL RECORD — VERIFIABLE DATA DUNS 426683105 · VAT PL9571026227
2009 Est.

Founded

Gdynia, PL · EU-based

↳ KRS 0000336317

0

QA Complaints

Across all production batches

↳ Internal QMS · since 2009

4

ISO Certifications

9001 · 22000 · 22716 · 27001

↳ Auditor: POLCARGO GROUP Ltd.

100M+

Softgels / Month

Three independent lines

↳ Production capacity, 2025

40+

Markets Served

EU · US · APAC · MENA

↳ Active export destinations

80%

Projects Declined

Science-gate qualification

↳ Internal policy · Science First™

ACTIVE CERTIFICATIONS Auditing body: POLCARGO GROUP Ltd. · Valid through 2029
STANDARD / REGISTRATION SCOPE STATUS
PN-EN ISO 9001:2015 Global Quality Management System (QMS) ACTIVE
PN-EN ISO 22000:2018 Food Safety Management System (FSMS) ACTIVE
PN-EN ISO 22716:2009 GMP for Cosmetics & Nutraceuticals ACTIVE
PN-EN ISO/IEC 27001:2023 Information Security Management (ISMS) ACTIVE
U.S. FDA Registration Federal Food Facility Registration (US) ACTIVE
HACCP / GHP / GMP Codex Alimentarius — Integrated System ACTIVE

All metrics are internally verifiable. Certification documents available under NDA upon request.

WSE Filing Reference: Adiuvo Investments S.A. Annual Board Report (Warsaw Stock Exchange, 2017) · DOC.20170412.26931757

ISO 27001:2023 Certified

Information Security — Audited by POLCARGO GROUP Ltd

Zero Conflict — Contractual Guarantee

Mutual NDA from Day One

U.S. FDA Registered Facility

Federal Compliance — Global Export Ready

17 Years · Zero QA Complaints

Operational Excellence — Verifiable Public Record

Why the World's Most Selective Formulators Choose Olympia

Every partnership is a long-term scientific collaboration — not a transaction.

Zero Competitive Conflict — Structural, Not Procedural

We have never launched a consumer brand. Your IP is the only product we protect. ISO 27001:2023 ensures this remains mathematically impossible to violate.

17 Years. Zero QA Failures. Verifiable.

A mathematical consequence of rejecting 70%+ of project inquiries and accepting only scientifically defensible formulations with documented clinical rationale.

Proprietary Technologies Unavailable Elsewhere

Vegicoll® plant-based collagen analog, Cambridge-licensed micellar systems, and AI-verified formulation safety.

Exclusive IP Acquisition Path

Strategic partners can negotiate sole exclusivity — one partner per technology. Once agreed, the technology is permanently off-market.

The Access Architecture

Access is structured around scientific alignment — not selected from a menu.

Qualification Dossier Review

Entry-level strategic screening for executive teams validating transfer risk, clinical fit, and IP defensibility.

  • Therapeutic thesis triage summary
  • Targeted dossier shortlisting
  • Pre-NDA strategic fit scoring
  • Executive screening call (admission dependent)
SUBMIT CLINICAL PROTOCOL

Strategic Diligence Track

NDA-protected diligence for teams preparing high-value launch, transfer, or buyout-readiness mandates.

  • Full technical dossier room access
  • Priority scientific diligence sessions
  • Exclusivity pathway negotiation
  • NDA-protected transfer workshops
  • Dedicated executive contact
REQUEST Q4 ALLOCATION

Exclusive Asset Transfer Mandate

Single-partner lock for defined technology including IP transfer, regulatory hand-off, and controlled industrial onboarding.

  • Exclusive IP acquisition rights
  • Full regulatory dossier transfer
  • Manufacturing transition control
  • Strategic co-development option
  • ISO 27001 protected data room
SUBMIT CLINICAL PROTOCOL

How Partner Access Works — Step by Step

  1. 01

    Protocol Submission

    Submit executive mandate details, transfer objectives, and target therapeutic domain for first-pass qualification.

  2. 02

    NDA & Diligence Gate

    Mutual NDA and intent framing are completed before proprietary documents enter diligence workflows.

  3. 03

    Scientific Diligence Session

    Focused board-level session to stress-test formulation strategy, risk posture, and exclusivity thesis.

  4. 04

    Allocation Decision

    Qualified teams receive data-room access and proposed allocation terms for exclusivity or co-development.

Explore Our Published Research

Browse Research Library 10 Tech Advantages Olimpia Baranowska

Ready to Access
the Full R&D Dossiers?

Every dossier is protected under ISO 27001:2023 and backed by a contractual zero-conflict guarantee. Begin your application today.

SUBMIT CLINICAL PROTOCOL

RELATED INTELLIGENCE

Supplement Formulation Technology Liposomal, micellar and nano-delivery systems available to partners EXPLORE › Physician Brand Supplement CDMO Clinical manufacturing pathway for physician-led supplement brands EXPLORE › FSMP & Medical Food Manufacturing EU Reg. 2016/128 clinical nutrition production for partner programs EXPLORE › R&D Intelligence Hub Full-depth clinical evidence dossiers available to registered partners EXPLORE › Science-First Manifesto — Our Partnership Standard We partner only with operators who share our evidence-based medicine commitment EXPLORE ›